Abbott Laboratories (ABT)
Company Profile: Abbott Labs is engaged in the discovery, development, manufacture, and sale of a broad and diversified line of health care products.1-Year Total Return: -12% Schoenstein's Take: In whittling down the list of possible investment ideas, Schoenstein says the Jensen Portfolio looks for companies with recurring revenue streams -- something that protects against real downturns -- as well as something in the business that gives a company an advantage over their competition, assuming they're investing in those advantages that they've created. In the healthcare space, which represents 21.4% of the portfolio, that is found in patent protection. Abbott Labs, at a portfolio weighting of 4.3%, isn't the largest health-care position the portfolio has but it has the most attractive characteristics. As they pertain to Abbott, there are competitive barriers to entry in the pharmaceutical space, plus patent protection in the device space, Schoenstein says. "They've got good device products, like stents, which have been quite well received," he says. "But you also have nutritionals, which has a strong platform here in the U.S. that they are taking to emerging markets. There is also the idea that pharmaceuticals have to be the branded, patented ones. Branded generics can be very powerful growth engines for companies like Abbott." In addition to targeting the key baby-boomer demographic, which is reaching the retirement age and is taking advantage of healthcare to live longer and healthier lives, Abbott offers investors exposure to emerging markets. "You're seeing people consuming healthcare in order to improve the quality of their lives," Schoenstein says. "[Abbott has] been making acquisitions in countries like India, where they are acquiring branded generics that they can offer at a lower-price point to emerging market populations."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV